"Patients who started low (well controlled)  and took ABET did better than people who started low and were on placebo (i.e. statin only). Were  the ABET peeps more statin compliant? Is  there is some kind of statin synergy here …  smh."

Nice summary DebKCardsPA. Personally, I don't think this has anything to do with statin compliance. In slide 32, looking at the below median vs. above median LDL-C endpoint data in the placebo groups, the low LDL-C group experienced 12% more 3-point MACE events (78/597 vs. 71/606) than the high LDL-C group, and this seems to be entirely explained by increased CV death (31/597 vs. 24/606); little to no difference in stroke and non-fatal MI. I would have expected a more statin compliant population to have a lower risk due to the LDL-C and hsCRP reductions associated with more compliant statin use.

BDAZ